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Abstract 
 
Background and aims: Inflammatory bowel disease, a disease 
previously thought to afflict predominantly people of western countries, 
has not gained the awareness and publicity among Sudanese clinicians 
and pathologists. The aim of this study is to enlighten this dark area and 
provide some epidemiologic, clinical and pathologic data on 
inflammatory bowel disease in Sudanese patients. 
Methods: Patients diagnosed with inflammatory bowel disease at Soba 
University Hospital in the period 2006-2010 were retrospectively selected 
for the study. Clinical and endoscopic data were collected. Tissue blocks 
were retrieved and processed into H&E slides. The slides were reviewed 
and our observations compared to those on the original histopathology 
reports. Any discrepancy between the two made the case excluded. All 
the data thus obtained was compiled into a checklist for each individual 
case and analysed electronically.  
Results: Seventy two cases of inflammatory bowel disease were found in 
the study period, 42 (58%) with ulcerative colitis, 15 (21%) with Crohn’s 
disease and 15 (21%) with a label of indeterminate colitis. More cases 
were diagnosed in the last three years of the study compared to the first 
two. The age range was 14-87 years with the peak for ulcerative colitis 
VII 
between 51-60 years and for Crohn’s disease between 31-40 years. 
Seventy two percent of the study population were males with a higher 
observed prevalence among males for both ulcerative colitis and Crohn’s 
disease. Seventy percent of the cases were from patients residing at 
central relatively more urbanised areas of the country. A third of the cases 
of Crohn’s disease were diagnosed from resection specimens compared to 
none of ulcerative colitis cases. Granulomas were demonstrated in 60% 
of Crohn’s disease patients compared to only 2% of ulcerative colitis 
cases. Further, granulomas in Crohn’s disease patients were more 
frequent in resection than in biopsy materials. Dysplasia was found in 
12.5% of the whole study population. Among patients with ulcerative 
colitis and Crohn’s disease, dysplasia was found in 19% and 7% 
respectively. However, the association between frequency of dysplasia 
and disease duration was difficult to estimate because of paucity of data. 
Conclusion: The number of new inflammatory bowel disease cases is on 
the rise. A high volume of cases diagnosed as indeterminate colitis is 
noted. Well designed epidemiologic studies are needed to verify the 
issues of disease locales and the relation of disease duration to the 
frequency of dysplasia.     
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 ﺘﺨﻠﺺــاﻟﻤﺴ
ﺍﻟﻭﻋﻲ ﻭ ﺍﻟﺸﻬﺭﺓ ﻋﻨﺩ ﺍﻻﻁﺒﺎﺀ ﻟﻡ ﻴﻜﺘﺴﺏ ﺩﺍﺀ ﺍﻻﻤﻌﺎﺀ ﺍﻻﻟﺘﻬﺎﺒﻲ ﻤﺴﺘﻭﻯ : ﺍﻟﻤﻘﺩﻤﺔ ﻭﺍﻻﻫﺩﺍﻑ
ﻭﺍﺨﺘﺼﺎﺼﻲ ﻋﻠﻡ ﺍﻻﻤﺭﺍﺽ ﻓﻲ ﺍﻟﺴﻭﺩﺍﻥ ﻭﺫﻟﻙ ﻷ ﻥ ﺍﻻﻋﺘﻘﺎﺩ ﺍﻟﻐﺎﻟﺏ ﻜﺎﻥ ﺍﻨﻪ ﻴﺼﻴﺏ ﺴﻜﺎﻥ 
ﺘﻬﺩﻑ ﻫﺫﻩ ﺍﻟﺩﺭﺍﺴﺔ ﺍﻟﻰ ﺍﻟﻘﺎﺀ ﺍﻟﻀﺅ ﻋﻠﻰ ﻫﺫﻩ ﺍﻟﻤﻨﻁﻘﺔ ﺍﻟﻤﻅﻠﻤﺔ  .ﺍﻟﺩﻭل ﺍﻟﻐﺭﺒﻴﺔ ﺒﺸﻜل ﺃﺴﺎﺴﻲ
ﻋﻥ ﻫﺫﺍ ﺍﻟﻤﺭﺽ ﻭ ﺍﻟﺒﺎﺜﻭﻟﻭﺠﻴﺔ , ﻭ ﺍﻟﺴﺭﻴﺭﻴﺔ , ﻭﺫﻟﻙ ﻤﻥ ﺨﻼل ﺘﻭﻓﻴﺭ ﺒﻌﺽ ﺍﻟﻤﻌﻠﻭﻤﺎﺕ ﺍﻟﻭﺒﺎﺌﻴﺔ 
 .ﺒﺎﻟﺴﻭﺩﺍﻥ
ﺘﻡ ﺃﺨﺘﻴﺎﺭ ﺍﻟﻤﺭﻀﻰ  ﻟﻠﻤﺸﺎﺭﻜﺔ ﻓﻲ  ﻫﺫﻩ ﺍﻟﺩﺭﺍﺴﺔ ﻤﻥ ﺍﻟﻤﺭﻀﻰ ﺍﻟﺫﻴﻥ ﺘﻡ ﺘﺸﺨﻴﺼﻬﻡ : ﺍﻟﻤﻨﻬﺠﻴﺔ
ﻭﺫﻟﻙ ﺒﺄﺜﺭ ﻡ 0102 – 6002ﺒﺩﺍﺀ ﺍﻻﻤﻌﺎﺀ ﺍﻻﻟﺘﻬﺎﺒﻲ ﻓﻲ ﻤﺴﺘﺸﻔﻲ ﺴﻭﺒﺎ ﺍﻟﺠﺎﻤﻌﻲ ﻓﻲ ﺍﻻﻋﻭﺍﻡ 
ﻜﻤﺎ ﺘﻤﺕ  .ﺘﻡ ﺘﺠﻤﻴﻊ ﺍﻟﻤﻌﻠﻭﻤﺎﺕ ﻭ ﺫﻟﻙ ﻋﻥ ﻁﺭﻴﻕ ﺇﺴﺘﻤﺎﺭﺓ ﺒﻴﺎﻨﺎﺕ ﻟﻌﺩﺩ ﻤﻥ ﺍﻟﻤﺘﻐﻴﺭﺍﺕ .ﺭﺠﻌﻲ
ﻤﺭﺍﺠﻌﺔ ﻤﻼﺤﻅﺎﺕ ﺍﻟﻤﺭﻀﻰ ﻭ ﺸﺭﺍﺌﺢ ﻋﻠﻡ ﺍﻻﻤﺭﺍﺽ ﺍﻟﻤﺼﺒﻭﻏﺔ ﺒﺎﻟﻬﻴﻤﺎﺘﻭﻜﺴﻠﻴﻥ ﺍﻟﺨﺎﺼﺔ 
 .ﺒﺎﻟﻤﺭﻀﻰ ﻭ ﺘﻭﺜﻴﻘﻬﺎ
ﺤﺎﻟﺔ %(85) 24 ,ﺤﺎﻟﺔ ﻤﺸﺨﺼﺔ ﺒﺩﺍﺀ ﺍﻻﻤﻌﺎﺀ ﺍﻻﻟﺘﻬﺎﺒﻲ ﺃﺜﻨﺎﺀ ﻓﺘﺭﺓ ﺍﻟﺩﺭﺍﺴﺔ 27ﻭﺠﺩﺕ : ﺍﻟﻨﺘﺎﺌﺞ
ﺤﺎﻟﺔ ﺒﺩﺍﺀ %(   12) 51,ﻤﻥ ﻫﺫﺩ ﺍﻟﺤﺎﻻﺕ ﺸﺨﺼﺕ ﻋﻠﻰ ﺃﻨﻬﺎ ﺍﻟﺘﻬﺎﺏ ﺍﻟﻘﻭﻟﻭﻥ ﺍﻟﺘﻘﺭﺤﻲ ﻭ 
ﻜﺎﻨﺕ  ﺍﻟﺤﺎﻻﺕ ﺍﻟﻤﺸﺨﺼﺔ ﻓﻲ ﺍﻟﺜﻼﺙ ﺴﻨﻭﺍﺕ . ﺤﺎﻟﺔ ﻏﻴﺭ ﻤﺼﻨﻔﺔ %(  12)  51, ﻜﺭﺍﻭﻥ 
 – 41ﺘﺭﻭﺍﺡ ﺍﻟﻤﺩﻯ ﺍﻟﻌﻤﺭﻱ ﻤﺎ ﺒﻴﻥ. ﺍﻻﺨﻴﺭﺓ ﺃﻜﺜﺭ ﻤﻥ ﺤﺎﻻﺕ ﺍﻟﺘﻲ ﺴﺠﻠﺕ ﻓﻲ ﺍﻟﺴﻨﺘﻴﻴﻥ ﺍﻻﻭﺍﺌل 
 16 –  05ﺘﺭﻜﺯﺕ ﻤﻌﻅﻡ ﺤﺎﻻﺕ ﺍﻟﺘﻬﺎﺒﺎﺕ ﺍﻟﻘﻭﻟﻭﻥ ﺍﻟﺘﻘﺭﺤﻲ ﻓﻲ ﺍﻟﻔﺌﺔ ﺍﻟﻌﻤﺭﻴﺔ ﻤﺎﺒﻴﻥ , ﺴﻨﺔ  78
ﻤﻥ %  27ﻤﺜل ﺍﻟﺫﻜﻭﺭ ﻨﺴﺒﺔ .ﺴﻨﺔ 04 – 13ﺴﻨﺔ ﻭﺘﺭﺍﻭﺡ ﺍﻟﻤﺩﻱ ﺍﻟﻌﻤﺭﻱ ﻟﺩﺍﺀ ﻜﺭﺍﻭﻥ ﻤﺎﺒﻴﻥ 
ﻤﻊ ﺯﻴﺎﺩﺓ ﻤﻠﺤﻭﻅﺔ ﻓﻲ ﻤﻌﺩل ﺍﻻﺼﺎﺒﺔ ﻟﻤﺭﻀﻲ ﺍﻟﺘﻬﺎﺏ ﺍﻟﻘﻭﻟﻭﻥ ﺍﻟﺘﻘﺭﺤﻲ (  27= ﻉ )ﺍﻟﻤﺭﻀﻲ 
ﻤﻥ ﺍﻟﺤﺎﻻﺕ ﻜﺎﻨﺕ ﻤﻥ ﺍﻟﺠﺯﺀ ﺍﻻﻭﺴﻁ ﻭ ﺍﻻﻜﺜﺭ ﺘﺤﻀﺭﺍﹰ ﻨﺴﺒﻴﺎﹰ ﺩﺍﺨل %  27ﻨﺴﺒﺔ .ﻭﺩﺍﺀ ﻜﺭﺍﻭﻥ 
ﻠﺙ  ﺤﺎﻻﺕ ﺩﺍﺀ ﻜﺭﺍﻭﻥ ﺘﻡ ﺘﺸﺨﻴﺼﻬﺎ ﻜﺎﻨﺕ ﻋﻴﻨﺎﺕ ﻤﺴﺘﺄﺼﻠﺔ ﺠﺭﺍﺤﻴﺎﹰ ﻜﻤﺎ  ﻭﺠﺩ ﺃﻥ ﺜ.ﺍﻟﻘﻁﺭ
 . ﻤﻘﺎﺭﻨﺔ ﺒﺼﻔﺭ ﻤﻥ ﺤﺎﻻﺕ ﺍﻟﺘﻬﺎﺏ ﺍﻟﻘﻭﻟﻭﻥ ﺍﻟﻤﺘﻘﺭﺡ 
ﻓﻘﻁ  ﻤﻥ ﺤﺎﻻﺕ  %  2ﻤﻥ ﺤﺎﻻﺕ ﺩﺍﺀ ﻜﺭﺍﻭﻥ ﻤﻘﺎﺭﻨﺔ ﺒﻨﺴﺒﺔ %  06ﻓﻲ ﺍﻟﻭﺭﻡ ﺍﻟﺤﺒﻴﺒﻲ ﺠﺩ ﻭ
ﺘﺄﺼﻠﺔ ﻤﻨﻬﺎ ﻓﻲ ﻜﺎﻥ ﺃﻜﺜﺭ ﻓﻲ ﺍﻟﻌﻴﻨﺎﺕ ﺍﻟﻤﺴ ﺍﻟﻭﺭﻡ ﺍﻟﺤﺒﻴﺒﻲﻜﻤﺎ ﻭﺠﺩ ﺃﻥ  .ﺍﻟﺘﻬﺎﺏ ﺍﻟﻘﻭﻟﻭﻥ ﺍﻟﻤﺘﻘﺭﺡ
ﻤﻥ ﺤﺎﻻﺕ ﺩﺍﺀ ﻜﺭﺍﻭﻥ ﻭ ﺍﻟﺘﻬﺎﺏ ﺍﻟﻘﻭﻟﻭﻥ %  7ﻭ %  91ﻭ ﻅﻬﺭ ﺍﻟﺘﻨﺴﺞ ﻓﻲ  .ﻋﻴﻨﺎﺕ ﺍﻟﺨﺯﻉ
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1. Introduction and Literature Review 
 
1.1 Anatomy and structure of the gastrointestinal tract: 
The gastrointestinal system is essentially a muscular tube lined by a 
mucous membrane that exhibits regional variations reflecting the 
changing functions of the system from mouth to anus(1). 
Ingestion and initial fragmentation of food occur in the oral cavity, 
resulting in the formation of a bolus of food; this is then conveyed to the 
oesophagus by the action of the tongue and pharyngeal muscles during 
swallowing. Secretion of saliva from major and minor salivary glands 
helps in fragmentation and lubricates the food for swallowing (1). 
The oesophagus conducts food from the oral cavity to the stomach where 
fragmentation is completed and digestion started. Initial digestion, 
accompanied by intense muscular action of the stomach wall, converts 
the stomach contents to a semi-digested liquid called chyme. Chyme is 
squirted through a muscular sphincter, the pylorus, into the duodenum, 
the short first part of the small intestine. Digestive enzymes from a large 
exocrine gland, the pancreas, enter the duodenum together with bile from 
the liver via the common bile duct. Bile contains excretory products of 
liver metabolism, some of which act as emulsifying agents necessary for 
fat digestion. The duodenal contents pass onwards along the rest of the 
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small intestine where the process of digestion is completed and the main 
absorptive phase occurs. The middle segment of the small intestine is 
called the jejunum and the distal segment the ileum. There is no distinct 
anatomical boundary between these two parts of the small bowel(1). 
The liquid residue from the small intestine passes through the ileocaecal 
valve, into the large intestine. Here, water is absorbed from the liquid 
residue, which becomes progressively more solid as it passes towards the 
anus. The capacious first part of the large intestine is called the caecum, 
from which projects a blind-ended sac, the appendix. The next part of the 
large intestine, the colon, is divided anatomically into ascending, 
transverse, descending and sigmoid segments, although histologically the 
segments are indistinguishable from one another. The terminal portion of 
the large intestine, the rectum, is a holding chamber for faeces prior to 
defaecation via the anal canal (1). 
The structure of the gastrointestinal tract (GIT) conforms to a general 
plan that is clearly evident from the oesophagus to the anus. 
The gastrointestinal tract has four distinct functional layers: mucosa, 
submucosa, muscularis propria and adventitia. 
• Mucosa. The mucosa is made up of three components: the epithelium, 
a supporting lamina propria and a thin smooth muscle layer, the 
muscularis mucosae, which produces local movement and folding of 
the mucosa. At four points along the tract, the mucosa undergoes 
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abrupt transition from one form to another: the gastro-oesophageal 
junction, the gastroduodenal junction, the ileocaecal junction and the 
recto-anal junction.  
• Submucosa. This layer of loose collagenous supporting tissue supports 
the mucosa and contains the larger blood vessels, lymphatics and 
nerves.  
• Muscularis propria. The muscular wall proper consists of smooth 
muscle that is usually arranged as an inner circular layer and an outer 
longitudinal layer. In the stomach only, there is an inner oblique layer 
of muscle. The action of the two layers, at right angles to one another, 
is the basis of peristaltic contraction for propelling food particles.  
• Adventitia. This outer layer of loose supporting tissue conducts the 
major vessels, nerves and variable adipose tissue. Where the gut lies 
within the abdominal cavity (peritoneal cavity), the adventitia is 
referred to as the serosa (visceral peritoneum) and is lined by a 
simple squamous epithelium (mesothelium). Elsewhere, the 
adventitial layer merges with retroperitoneal tissues. 
There are four basic mucosal types found in the gastrointestinal tract, 
which can be classified according to their main function: 
Protective. This type is found in the oral cavity, pharynx, oesophagus 
and anal canal. The surface epithelium is of stratified squamous type and 
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although not keratinised in humans, it may be keratinised in animals that 
have a coarse diet, e.g. rodents, herbivores. 
Secretory. This type occurs only in the stomach. The mucosa consists of 
long, closely packed tubular glands that are simple or branched 
depending on the region of the stomach. 
Absorptive. This mucosal form is typical of the entire small intestine. 
The mucosa is arranged into finger-like projections, called villi, which 
increase surface area with intervening short glands called crypts. In the 
duodenum, some crypts extend through the muscularis mucosae to form 
submucosal glands called Brunner's glands. This is the major 
histological feature that differentiates the duodenum from the jejunum 
and ileum. 
Absorptive/protective. This form lines the entire large intestine. The 
mucosa is arranged into closely packed, straight tubular glands consisting 
of cells specialised for water absorption and mucus-secreting goblet cells 
to lubricate the passage of faeces(1). 
1.1.1 Mucosa of the large intestine 
The mucosa is the same from caecum to rectum. It is folded in the non-
distended state. Immediately above the anal valves, the mucosa forms 
longitudinal folds called the columns of Morgagni. The muscularis 
mucosae is a prominent feature of the large intestinal mucosa; rhythmic 
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contractions prevent clogging of the glands and enhance expulsion of 
mucus(1). 
Consistent with its functions of water absorption and faecal lubrication, 
the mucosa consists of cells of two types: absorptive cells and mucus-
secreting goblet cells. These are arranged in closely packed straight 
tubular glands or crypts, which extend to the muscularis mucosae. As 
faeces pass along the large intestine and become progressively 
dehydrated, the mucus becomes increasingly important in protecting the 
mucosa from trauma. The Alcian blue method stains goblet cell mucus a 
greenish-blue colour while the absorptive cells remain poorly stained. 
Goblet cells predominate in the base of the glands, whereas the luminal 
surface is almost entirely lined by columnar absorptive cells(1). 
The tall columnar absorptive cells have oval basal nuclei; in contrast, 
goblet cell nuclei are small and condensed. Stem cells at the base of the 
glands continually replace the epithelium. Lamina propria fills the space 
between the glands and contains numerous blood and lymphatic vessels 
into which water is absorbed. The lamina propria also contains collagen 
as well as lymphocytes and plasma cells. These form part of the defence 
mechanisms against invading pathogens along with intraepithelial 
lymphocytes and the lymphoid aggregates, found in the lamina propria 
and submucosa(1). 
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1.2 Inflammatory bowel disease: 
Inflammatory bowel disease (IBD) is a chronic inflammatory disease of 
largely unknown aetiology and speculative pathogenetic mechanisms. 
The two major forms are ulcerative colitis (UC) and Crohn’s disease 
(CD). They share many clinical, radiological and pathological features 
that pose difficulties and pressures to diagnosing pathologists. However, 
a correct specific diagnosis is essential for the optimal management of the 
patient.  
Both CD and UC are predominantly diseases of young adults, occurring 
with a peak incidence between 15 and 30 years of age(2, 3). Epidemiologic 
studies show that the incidence and prevalence of IBD vary significantly 
depending on the patient’s geographic location and racial or ethnic 
background. Incidence rates for both diseases are higher and rising more 
in urban than in rural areas, and in industrialized than nonindustrialized 
countries. While the incidence of Crohn’s disease has increased strikingly 
in many areas, the incidence of ulcerative colitis has remained fairly 
stable in most(4). In the United States specifically, an estimated 1 million 
individuals have IBD with about 30,000 new cases reported each year. 
The incidence is evenly divided between UC and CD(5). 
The incidence of IBD has either continued to increase or has stabilized at 
a high rate in most developed countries, whereas the incidence continues 
to rise in regions where IBD had been less common (6). In Sudan, there are 
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no epidemiologic studies indicating the exact prevalence and incidence of 
IBD. Khalifa et al described a series of 85 Sudanese patients with 
inflammatory bowel disease in 2001 from one centre(7). The speciality of 
gastroenterology is flourishing in Sudan with the establishment of many 
dedicated units in many hospitals. Large numbers of endoscopies and 
endoscopic biopsies are being performed regularly, and some of these 
turn out to be IBD. We are now seeing many patients and specimens with 
UC and CD, entities previously thought to be rare and only of academic 
interest. 
The pathophysiology of IBD involves complex interactions between 
genetic, environmental, and immunologic factors. Genetic linkage studies 
have identified a number of potential genetic susceptibility loci for IBD 
named IBD1, IBD2, IBD3, IBD4, IBD5 and IBD6, among others, 
containing  different gene sequences, some linked to  UC, other to CD 
and still others to both diseases(8).   
Environmental influences have a well established role in the pathogenesis 
of IBD. Environmental changes modulate the development of the 
mucosal immune system or the indigenous flora and that are linked to the 
higher incidence rates in developed countries include improved hygiene, 
consumption of sterile or at least noncontaminated foods, childhood 
vaccinations, and increased age at first exposure to a variety of intestinal 
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pathogens(9). Smoking decreases the risk for the development of UC, but 
exacerbates and aggravates CD(10).  
Both UC and CD are disorders of immunity. It is currently believed that 
the main abnormality responsible for the development of inflammation in 
these disorders is an exaggerated T cell response to commensal bacteria 
and other pathogens(11). 
1.2.1 Crohn’s Disease: 
The disease was named for American gastroenterologist Burrill Bernard 
Crohn, who, in 1932, together with two colleagues, described a series of 
patients with inflammation of the terminal ileum, the area most 
commonly affected by the illness(12). For this reason, the disease has also 
been called regional ileitis or regional enteritis. Approximately 30% to 
40% of patients have small bowel involvement only; 30% to 40% have 
ileocolonic involvement; and only 10% to 20% have exclusive 
involvement of the colon (Crohn’s colitis [CC]). CD can be categorized 
by its clinical behaviour or pattern of disease, including inflammatory, 
fistulising, or fibrostenotic disease. The pattern of disease determines the 
signs, symptoms, and complications. Most patients with CD present 
during their second to fourth decades of life, although there is a smaller 
peak between the fifth and seventh decades of life. Although all ethnic 
groups may be affected, CD is more prevalent among white North 
Americans, northern Europeans, Ashkenazi Jews, Scandinavians, and the 
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Welsh. CD is marginally more frequent in women (female-to-male ratio 
range, 1:1 to 1.8:1) (13). 
The cause of CD is unknown but probably involves a combination of 
environmental factors (e.g., luminal bacteria or infectious agents), 
abnormalities in immune regulation, and a genetic predisposition(14).  
1.2.1.1 Pathologic features: 
CD classically involves the distal 15 to 25 cm of the terminal ileum, often 
in association with disease involving the right colon, but any part of the 
GIT may be involved. Diseased segments are frequently separated by 
intervening skip areas of essentially endoscopically normal gut. Usually 
there is rectal sparing. The external surface appears hyperemic. Fat 
encircles the antimesenteric serosal surface (creeping fat). Initially the 
intestinal wall remains pliable, but with disease progression, it becomes 
increasingly fibrotic and rigid. Eventually a stricture may develop 
resulting in obstruction(14). 
The earliest grossly visible mucosal change is the formation of aphthous 
ulcers. These are more obvious in the colon because villi tend to obscure 
them in the small intestine. Aphthous ulcers eventually enlarge into 
continuous, serpiginous or linear ulcers. The intervening mucosa may 
appear reddened and swollen giving a cobblestone appearance. 
Inflammatory polyps and pseudopolyps are seen in CD. Fistulas and 
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adhesions occur particularly in those with small intestinal disease. 
Perforation of the intestine may occur but is uncommon, affecting 1.5% 
of CD patients. CD is often complicated by strictures in the small and 
large intestine which may cause partial, intermittent obstruction. 
Strictures may also develop in patients with IBD complicated by 
malignant change(14). 
Microscopic findings: 
It is easier to diagnose CD in resection specimens than in biopsy material 
because they are likely to exhibit the transmural nature of the changes and 
the classic features that are found in the deeper layers of the wall. All the 
mucosal histological features, even granulomas found in CD are 
nonspecific if they are interpreted in isolation, and this diagnosis is based 
on the appreciation of heterogeneity of abnormalities, their patchy 
distribution between biopsy specimens procured from the same region of 
the colon, and their patchy distribution across the breadth of each tissue 
fragment.  Biopsy specimens from the same region usually have different 
appearances: normal, inflamed, and ulcerated fragments can be admixed. 
Often, numerous tissue fragments from separately identified regions of 
the bowel in conjunction with clinical and endoscopic information are 
necessary to make a diagnosis of CD.  
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It is usually not possible to make a definitive diagnosis of CD without 
clinical and endoscopic information, because treated UC can be 
morphologically identical to treated or untreated CD(14).  
Mucosal inflammatory infiltrate 
Inflammatory foci in CD can show an even admixture of cells, or they 
may be composed predominantly of lymphocytes and plasma cells, 
neutrophils, or granulomas. Differences in the predominant cell type 
between foci of mucosal involvement are a major component of the 
heterogeneity characteristic of CD. Well-circumscribed, focal collections 
of lymphocytes that surround several crypts (lymphoid aggregates) 
simulate normal lymphoid follicles. However, lymphoid aggregates in 
CD reveal crypts within their centres unlike normal lymphoid follicles 
with crypts pushed to the periphery. Neutrophils in CD are also focal and 
patchy. They can be admixed with lymphoplasmacytic inflammation or 
can be the predominant cell in otherwise normal mucosa. Cryptitis and 
crypt abscesses can be found but are less prominent than in UC(14). 
Crypt injury and ulcers 
Crypt injury in active CD is usually not a homogeneous, cryptocentric 
process that produces extensive crypt destruction and abnormally shaped 
regenerative crypts typical of UC. Typically, one or several injured and 
inflamed crypts with focal mucin depletion are situated adjacent to 
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normal crypts. The injured crypts are focally infiltrated by neutrophils, 
and mucin depletion is limited to the epithelial cells immediately 
surrounding the focus of crypt injury (14).  
Ulcers develop with increasing activity and crypt and surface epithelial 
injury. Two types of ulcers are morphologically characteristic of CD-
aphthous ulcers and fissuring ulcers. Aphthous ulcers arise in focal, 
mildly active CD. They are well delineated, small, and superficial and are 
usually limited to two to four crypts. Aphthous ulcers can continue to 
expand and connect to form serpiginous or longitudinally predominant 
ulcers. Fissuring ulcers may extend through the bowel wall(14). 
Crypt architectural disarray and distortion 
Foci of lamina propria inflammation, edema, aphthous ulcers, and focal 
crypt injury produce an irregular distribution of crypts in the lamina 
propria. Variation in crypt size can also be seen if crypt injury has 
resulted in patchy crypt architectural disarray, a feature most easily 
appreciated at medium or low magnification. Sufficient crypt injury over 
time can produce crypt branching and shortening, resulting in 
architectural distortion indicative of chronicity. Crypt disarray is a feature 
of mucosal involvement in Crohn’s disease, similar to UC(14). 
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Chronic Crohn’s colitis 
Morphologic features of chronicity are important in the diagnosis of CD. 
However, establishing chronicity in CD may be difficult because crypt 
branching or shortening is usually focal, and isolated branched crypts can 
be interspersed between regions of normal bowel. Paneth cell and mucous 
(pyloric) gland metaplasia are both markers of chronicity. Although 
Paneth cell metaplasia is seen more often in UC, mucous gland 
metaplasia is present more often in CD and particularly in the small 
intestine.  Paneth cells are not normally found distal to the hepatic flexure 
and should be considered metaplastic if they are identified beyond this 
point. Mucous gland (pyloric gland) metaplasia is most commonly found 
in the caecum and the right colon(14). 
Lymphoid aggregates 
Lymphoid aggregates which may contain germinal centres generally lie at 
the mucosa- submucosal junctions as well as within deeper layers of the 
bowel wall. Lymphoid aggregates may form even in the absence of 
granulomas and may be quite helpful in the diagnosis of CD particularly 
if found in the submucosa or deep(14). 
Granulomas 
The presence of small, compact, sarcoid-like granulomas is a reliable 
histologic criterion for differentiating CD from UC. However, these 
granulomas should be distinguished from mucin granulomas that form 
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around ruptured crypts. Mucin granulomas have no diagnostic 
significance because they may be found in UC, CD, and other colitides. 
CD-associated granulomas are smaller and have more sharply defined 
edges than mucin granulomas. The macrophages within mucin 
granulomas usually have greater amounts of bubbly or clear cytoplasm 
caused by phagocytosis of mucin and crypt contents. Foreign body giant 
cells are usually not a component of CD granulomas but can be found in 
mucin granulomas. CD-associated granulomas are well-formed, non-
necrotizing and usually located in the submucosa, but occasionally can be 
found in the mucosa. They are diagnostic of CD if found in 
endoscopically normal mucosa remote from areas of ulceration in 
situations where foreign body or mucin granulomas are unlikely. They 
are present in 40% to 60% of CD patients. They may sometimes be found 
in lymph nodes, pancreas, mesentery, peritoneum, liver, lung, kidney, 
and, occasionally, bones, joints and skeletal muscle. The presence of 
necrotizing granulomas or a large number of granulomas should make 
one think about infectious lesions, such as tuberculosis, histoplasmosis, or 
yersiniosis(14). 
1.2.1.2 Management  
Patients with CD are treated medically, with limited surgical 
interventions indicated in CD-associated complications. Medical 
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treatment options include steroids, anti- inflammatory agents, 
immunosuppressive agents, antibiotics, and new biologic agents. Among 
the latter, anti TNF-alpha monoclonal antibody, infliximab, 
revolutionised the treatment of this disease. A surgical pouch procedure, 
which is frequently performed in patients with UC, is contraindicated in 
those with CD because of the increased morbidity associated with it(15). 
1.2.2 Ulcerative colitis: 
Ulcerative colitis is a chronic, episodic IBD in which the inflammation 
remains confined to the colon. It has a propensity to arise in adolescents 
and young adults, although there is a second incidence peak among 
middle aged men. It is slightly more common in males (13). Estimates of 
the annual incidence of UC in North America and Europe range from 4 to 
20 per 100,000 individuals(16). The incidence of UC appears to have 
equilibrated over the past two decades and is no longer increasing, unlike 
that of Crohn’s disease, which seems to be increasing in incidence(4). 
1.2.2.1 Pathologic features: 
Grossly, UC classically involves the rectum (in 95% of patients) with 
continuous involvement of the colon proximally. Although some cases 
involve only the rectum (proctitis), others involve the entire colon 
(pancolitis). The ileum is sometimes affected in patient with severe 
pancolitis (backwash ileitis). The mucosa often has a hemorrhagic or 
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granular appearance, and gross appearance depends in part on the activity 
of the disease. Histologically, untreated UC diffusely involves a region of 
the colon that usually starts at the anal verge and extends proximally in a 
contiguous fashion. All biopsy specimens from the same region of the 
colon have a similar appearance, and each biopsy fragment shows a 
homogeneous pattern of injury across its breadth(14). 
Inflammation 
UC is predominantly a lymphoplasmacytic process that for the most part, 
is confined to the mucosa. Dense, homogeneous lymphoplasmacytic 
inflammation expands and thickens the lamina propria and produces an 
irregular (luminal) surface. All biopsy specimens procured from the same 
region of the colorectum usually have a similar, uniform density of 
lymphoplasmacytic inflammation. The density of plasma cells is greatest 
in the basilar region of the lamina propria (basal plasmacytosis). 
Neutrophils may be scattered in the lamina propria or may cause active 
crypt injury (cryptitis) or form crypt abscesses. The density of neutrophils 
in untreated UC is also usually similar across each biopsy fragment and 
between biopsy fragments from the same region of the colon, resulting in 
similar degrees of mucin depletion in crypt epithelial cells. Crypt rupture 
can produce histiocytic aggregates and occasional giant cells around the 
focus, resulting in mucin granulomas. These should not be interpreted as 
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granulomas of CD. When a mucosal granuloma is identified, serial 
sections should be evaluated to determine if it is immediately adjacent to 
a ruptured crypt and hence is a mucin granuloma. The presence of 
eosinophils within a granuloma is often indicative of it being a mucin 
granuloma (14). 
Crypt injury and architectural distortion 
The hallmark morphologic feature of UC is crypt architectural distortion, 
characterized by irregularly arranged, branched and shortened crypts. 
Crypt injury in UC is usually similar both within and between biopsy 
fragments procured from the same region of the colon. Crypt architectural 
distortion is generally considered a hallmark of chronic colitis; however, 
any disease that can produce sufficient persistent crypt injury can result in 
crypt architectural distortion (14).  
Disease distribution 
Occasionally, the rectum can endoscopically appear to be free of active 
disease or to have less activity than the more proximal colon, suggesting 
rectal or relative rectal sparing. Histologically, the rectum is abnormal in 
most of these cases, with crypt architectural distortion and mild activity. 
UC limited to the rectum has been referred to as ulcerative proctitis. This 
disease is thought to be less severe and to have a lower rate of dysplasia 
and adenocarcinoma than cases of ulcerative pancolitis. Biopsies from 
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approximately 10 cm above the endoscopic end of active disease should 
be normal; otherwise, the patient should be classified as having left sided 
UC(14). 
Resolution Phase 
Most patients with UC enter into a resolution phase of decreasing activity 
and symptoms after an active colitis episode; this phase is 
morphologically characterized by decreasing activity and crypt injury, 
with crypt regeneration followed by crypt remodeling. Neutrophils and 
the accompanying crypt injury decrease first, which can produce a patchy 
appearance. Lymphocytes and plasma cells persist and are the last cells to 
vacate the mucosa. Decreased lymphoplasmacytic inflammation can also 
result in a patchy process. Healing of ulcers occurs by surface epithelial 
regrowth that secondarily develops downgrowth of crypt buds. Injured 
crypts heal from the base toward the surface. Initially, regenerative cells 
are cuboidal to columnar, with slightly basophilic cytoplasm. Mucin 
slowly reappears, first in cuboidal cells and later in goblet cells. Over 
time, goblet cells can become numerous. Crypt branching and focal 
shortening are usually prominent during the early resolution phase. 
Metaplastic Paneth cells appear within regenerative crypt bases in 
mucosa distal to the hepatic flexure. Together with crypt architectural 
distortion, basal plasmacytosis, and basally located lymphoid aggregates, 
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Paneth cell metaplasia can be used as a morphologic marker of previous 
significant crypt injury (chronic colitis)(14). 
Chronic ulcerative colitis 
The resolution period of decreasing activity lasts for several months in 
most patients and shifts imperceptibly into the phase of chronic ulcerative 
colitis (CUC). Between episodic active episodes, most CUC is either 
inactive or minimally active. Architecturally distorted crypts remain a 
hallmark sign of previous active colitis. The morphology is usually of a 
patchy colitis with regions of activity separated by inactive areas. Care 
must be taken not to misinterpret these patchy changes as representing 
Crohn’s disease (thus, clinical history is important)(14). 
1.2.2.2 Management  
Medical treatment options for patient with UC include anti-inflammatory 
agents, corticosteroids, immunosuppressive agents, biological agents 
including infliximab, and probiotics. Therapy may have profound effects 
on histology sometimes with resultant patchiness and apparent rectal 
sparing, features would otherwise suggest a diagnosis of CD. Clinical 
history is thus of utmost importance. Surgery can be performed in 
emergencies or otherwise electively. Elective surgery is indicated in cases 
of failed medical treatment, growth retardation in children, and the 
development of, or concern for, neoplastic transformation. Surgical 
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options include conventional proctocolectomy, colectomy with ileorectal 
anastomosis, and restorative proctocolectomy with ileal resorvoire 
(=Pouch procedure, a contraindicated procedure in patients with CD)(15). 
1.2.3 Indeterminate colitis: 
In approximately 5% of IBD cases, a definite diagnosis of UC or CD 
cannot be established, most commonly because of insufficient clinical, 
radiologic, endoscopic, or pathologic data or because of prominent 
overlapping features between these two disorders. In these circumstances, 
the term indeterminate colitis (IC) has been used. However, this is a 
grossly overused and misused term in IBD diagnostic pathology. It must 
be emphasized that IC is not a specific disease entity; it has no diagnostic 
criteria. Rather, it represents a provisional descriptive term to be used by 
pathologists only when a definite diagnosis of UC, CD, or another cause 
of chronic colitis cannot be established with the information available at 
the time of surgical sign-out. In fact, in most of the cases, the true nature 
of the patient’s underlying IBD usually becomes apparent during the 
ensuing years of follow-up, or when all of the patient’s clinical, 
endoscopic, and previous pathology material has been obtained and 
reviewed in detail. Pathologists often fall back on a diagnosis of IC when 
a definite diagnosis of UC or CD cannot be made on the basis of biopsy 
specimen analysis; this practice is highly discouraged. In other instances, 
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the diagnosis is used because of a lack of awareness about unusual 
variants of UC that can lead to apparent skip lesions in UC, or because of 
the unwillingness of pathologists to accept a particular finding, such as 
segmental disease, granulomatous inflammation, transmural lymphoid 
aggregates, or deep fissuring ulceration, as a diagnostic criterion for 
CD(17). In Sudan, we think that the term is abused and the percentage of 
cases diagnosed as IC is high. This is likely due to the attempts by 
pathologists to diagnose cases on the biopsy findings alone. 
1.3 Ancillary (serologic) diagnostic tests: 
In certain circumstances, serologic testing for antineutrophil cytoplasmic 
antibodies (ANCAs) and anti – Saccharomyces cerevisiae antibodies 
(ASCAs) may be helpful in classifying IC cases into UC or CD with high 
specificity. A newly developed serologic marker, termed CBir1, which 
represents an antibody associated with enteric bacterial flagellin antigens 
initially identified in a mouse model of colitis, has been shown to identify 
patients with CD not detected with other markers. Unfortunately, the use 
of ANCA, ASCA, and CBir1 has not been extensively studied for IC, and 
further investigation is needed(14). 
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1.4 Differential diagnosis of ulcerative colitis versus Crohn’s 
disease: 
Important features of untreated UC in biopsy specimens include diffuse 
involvement of the colorectum without skip lesions, lack of submucosal 
involvement, lack of granulomas (except those related to mucin), and lack 
of terminal ileum involvement (with the exception of a minor degree of 
inflammation associated with backwash ileitis). In resection specimens, 
diffuse continuous mucosal disease (including the rectum)—in the 
absence of deep fissuring ulceration, sinus tract formation, transmural 
lymphoid aggregates (away from areas of ulceration), small intestinal 
involvement (except in backwash ileitis), or granulomas, and in 
appropriate clinical, radiologic, and endoscopic settings—is a finding 
normally considered consistent with UC(14). 
Typical features of CD include segmental involvement, less severe 
disease in the distal colon than in the proximal colon, rectal sparing, 
submucosal inflammation, patchiness of inflammation, granulomas 
unrelated to mucin, terminal ileum involvement, upper GI involvement, 
and a less pronounced degree of mucosal architectural changes and mucin 
depletion compared with UC. Under normal circumstances, these features 
should be considered sufficient for a diagnosis of CD. However, in some 
cases, as in fulminant colitis, a definite diagnosis of UC or CD cannot be 
made because of the presence of overlapping features. Furthermore, 
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several exceptions to the classic pathologic features have been noted, and 
these may contribute to diagnostic confusion(14). 
1.5 The endoscopic biopsy in inflammatory bowel disease: 
The first decision is to determine if it is normal or abnormal. Once it is 
deemed that abnormal inflammatory changes are present, the next step is 
to determine whether they are acute or chronic. Crypt distortion, basal 
plasma cells, basally located lymphoid aggregates, and Paneth cell 
metaplasia (in the transverse and left colon) are typically the most helpful 
and most common histologic features indicative of chronic colitis, 
especially in IBD. Features of chronicity may be more subtle or focal in 
Crohn’s disease. Nevertheless, it is often quite difficult to differentiate 
between UC and CD on biopsy findings. In many respects, pathologists 
are held hostage by the type, quantity, and location of the biopsy material, 
and by the clinical information provided by the endoscopist. Thus, in 
most instances, it is not possible to know whether colon biopsies from a 
patient with IBD indicate UC or CD solely on the basis of analysis of 
biopsy specimens(14).  
1.6 Dysplasia in inflammatory bowel disease: 
1.6.1 Dysplasia in ulcerative colitis: 
Dysplasia is present in up to 90% of patients with UC and with 
carcinoma, both adjacent to and distant from the primary tumor. 
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Dysplasia often parallels the location of cancer and it is more often 
multifocal. The strongest risk factors for the development of dysplasia or 
carcinoma in UC are the extent and duration of disease. The incidence of 
dysplasia in UC is difficult to estimate. Recent studies suggest a 2% 
incidence of dysplasia after 10 years, 8% after 20 years, and 18% after 30 
years(18). 
1.6.1.1 Pathologic features 
Grossly, two general patterns of dysplasia occur in UC: flat 
(endoscopically undetectable) and raised (endoscopically detectable). 
They are graded in the same way but treated differently. Microscopically, 
atypical changes in UC are separated into three distinct categories—
negative for dysplasia, indefinite for dysplasia, and positive for dysplasia 
(low and high grade). Dysplastic epithelium shows cells with nuclear 
hyperchromatism and enlargement (often pencil shaped), a clumped 
chromatin pattern often with multiple nucleoli, and hypereosinophilic, 
mucin-depleted cytoplasm. Most importantly, dysplastic epithelium does 
not normally show maturation to the surface of the mucosa. Mitotic 
figures are often plentiful, and atypical mitotic figures are not uncommon. 
Architectural aberration is common as well. Dysplastic crypts tend to 
have more of a “back-to-back” configuration with little intervening 
lamina propria, which is sometimes associated with irregular crypt 
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budding, cystic change, villiform surface change, or cribriforming of the 
crypt lumen. In low-grade dysplasia, nuclear crowding and stratification 
is typical, but the nuclei are generally limited to the basal half of the cell 
cytoplasm. Other, less common features of low-grade dysplasia include 
dystrophic goblet cells and endocrine and Paneth cell metaplasia. With 
progression from low- to high-grade dysplasia, the cells acquire a more 
oval or round nuclear contour and show a greater nucleus-to-cytoplasm 
ratio, increased stratification of nuclei, and a more distinct loss of nuclear 
polarity. In addition, architecturally, a more complex crypt pattern is 
seen, with more back-to-back gland formation and distortion. The cells in 
high-grade dysplasia are normally larger and more pleomorphic. Mitotic 
figures, both typical and atypical, are more frequent and are usually 
present both in the upper levels of the crypt and in the surface epithelium. 
In general, the features of the most atypical portions of dysplastic mucosa 
determine the overall grade of dysplasia in any particular biopsy sample. 
1.6.2 Dysplasia in Crohn’s disease: 
Several studies suggest that given a similar duration and extent of disease, 
the risk for neoplasia is similar in CD and UC(19). In CD, there is also an 
increased risk for dysplasia and adenocarcinoma in excluded segments of 
bowel and in the small intestine. Most studies also support a dysplasia-
carcinoma sequence in CD similar to that which occurs in UC(20). The 
pathologic features of dysplasia in CD are also similar to those of UC; 
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dysplasia is classified in a similar manner (negative, indefinite, positive 
[low or high grade]).  
1.7 Justification 
We think that IBD is no longer a rare entity in Sudan. More patients are 
being diagnosed. On the contrary, many patients are misdiagnosed and 
keep wandering from one clinic to another. For proper case management, 
both gastroenterologists and pathologists must be aware of the proper 
diagnostic approach and defining features. There are few published data 
regarding the epidemiology and pathological patterns of inflammatory 
bowel disease in Sudanese patients. Also, of note is the increased 
incidence of colorectal cancer (CRC) in Sudanese patients, an occurrence 
that was supposed to be low, and the intimate link between CRC, 
dysplasia, and IBD. The aim of this study is to provide a baseline for 
reviewing the pathology of IBD in Sudanese patients. 
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1.8 Objectives: 
We are aiming at reviewing the cases diagnosed as IBD in Sudanese 
patients at Soba University Hospital in the last five years so as to provide 
epidemiologic and pathologic data to improve diagnosis of IBD.  
Our specific objectives are: 
1. To study the demographic variables of affected patients. 
2. To determine the relative frequencies of UC and CD and the 
magnitude of biopsies diagnosed as indeterminate colitis. 
3. To review the sites of bowel involvement and the relationship 
between specimen type (biopsy versus resection) and the final 
diagnosis. 
4. To determine the frequencies of granulomas and lymphoid 
aggregates in UC and CD specimens. 
5. To determine the frequency of dysplasia in each type and years to 
develop after initial presentation. 
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2. Materials and Methods 
 
2.1 Study design: 
This is a descriptive retrospective hospital-lab based study.  
2.2 Study area: 
The study takes place at Soba University Hospital (SUH) which has 
specialised medical and surgical gastrointestinal units. 
2.3 Study population: 
Patients diagnosed as IBD at SUH in the period 2006-2010.  
2.4 Inclusion criteria: 
All patients labelled as IBD in the period 2006-2010 whether from new or 
from follow up biopsies. Patients with a diagnosis of IBD made before 
2006 and have follow up biopsies during the study period are included. 
Clinical and endoscopic data must be available in addition to tissue 
blocks or H&E slides.   
2.5 Exclusion criteria: 
Patient with inadequate clinical data, with no available endoscopy reports 
or with missing original pathology reports are excluded. Also excluded 
are those cases in which both the tissue blocks and H&E slides are 
missing. Those with missing tissue blocks and available but poorly 
prepared slides with difficulty interpretation are also excluded. Any 
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discrepancy between our observations and those in the original report 
makes the case excluded.  
2.6 Data collection: 
Patients with a diagnosis of IBD (UC, CD or IC) based on clinical, 
endoscopic and pathological features are selected for the study. The 
archives of the histopathology laboratory and those of the medical and 
surgical GI units are reviewed and IBD cases in the period 2006-2010 
selected. Information is gathered from the clinical notes, endoscopy 
reports and histopathology reports. All the data obtained are compiled 
into a checklist (questionnaire) for each individual case. 
Formalin fixed paraffin embedded tissue blocks are retrieved from the 
histopathology laboratory and processed into H&E stained slides. If the 
blocks are not available, readymade slides are collected to be reviewed 
and then returned to the laboratory. All the slides thus obtained are 
reviewed by a consultant histopathologist in light of the clinical and 
endoscopic information. Our observations are transcribed into the check 
list (questionnaire) and then compared to those in the original 
histopathology reports. Any discrepancy between the two makes the case 
invalid and thus excluded. 
In our search for and grading of dysplasia we followed the 4-tiered 
system proposed by Riddell et al in 1983(49). Dysplastic changes are 
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categorised into: negative for dysplasia, indefinite for dysplasia and low 
and high grade dysplasia. 
2.7 Data analysis: 
A master sheet with data compiled from all the observations for all the 
patients is prepared. Data is analysed electronically using Statistical 
Package for Social Science (SPSS) with the aid of a statistician. 
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3. Results  
 
Table 1: The relative frequencies of each of the three diagnostic 
categories 
 
 
Diagnosis Frequency Percent 
UC 42 58.3 
CD 15 20.8 
IC 15 20.8 
Total 72 100.0 
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Figure 1: The number of IBD diagnoses made between 2006 and 2010  
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Figure 2a: The distribution of the study population according to age 
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Table 2: Types of specimens obtained from the 72 IBD patients 
regardless of the specific diagnosis 
 
Specimen Frequency Percent 
Biopsy 67 93.1 
Resection 5 6.9 
Total 72 100.0 
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Table 3: The frequency of diagnosing each category from resection and 
biopsy specimens 
   
Diagnosis 
 
Specimen 
Total 
 
Biopsy Resection 
UC 42 0 42 
CD 10 5 15 
IC 15 0 15 
Total 67 5 72 
 
P = 0.00  
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Table 4: The relative frequencies of UC, CD and IC involving the 
terminal ileum  
  
Diagnosis 
 
Ileum 
Total 
 
Yes No 
UC 0 42 42 
CD 10 5 15 
IC 1 14 15 
Total  11 61 72 
 
P = 0.00 
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Table 5: The relative frequencies of UC, CD and IC involving the right 
colon 
 
Diagnosis 
 
Rt. Colon 
Total 
 
Yes No 
UC 3 39 42 
CD 6 9 15 
IC 3 12 15 
Total 12 60 72 
 
P = 0.13 
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Table 6: The relative frequencies of UC, CD and IC involving the 
transverse colon  
 
Diagnosis 
T. colon 
Total Yes   No  
UC 1 41 42 
CD 1 14 15 
IC 2 13 15 
Total 4 68 72 
 
P = 0.11 
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Table 7: The relative frequencies of UC, CD and IC involving the left 
colon 
 
Diagnosis 
 
Lt. colon 
Total 
 
Yes  No  
UC 9 33 42 
CD 0 15 15 
IC 2 13 15 
Total 11 61 72 
 
P = 0.04 
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Table 8: The relative frequencies of UC, CD and IC involving the rectum  
 
Diagnosis 
 
Rectum 
Total 
 
Yes No  
UC 23 19 42 
CD 3 12 15 
IC 7 8 15 
Total 33 39 72 
 
P = 0.05 
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Table 9: The relative frequencies of UC, CD and IC involving the colon 
(exact site not specified) 
 
  
Diagnosis 
Colon 
Total Yes  No  
UC 19 22 41 
CD 4 11 15 
IC 4 11 15 
Total 27 44 71 
 
P = 0.12 
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Table 10: The frequency of granulomas in relation to diagnosis  
 
Diagnosis 
 
Granuloma 
Total 
 
Yes No  
UC 1 41 42 
CD 9 6 15 
IC 0 15 15 
Total 10 62 72 
 
P = 0.00 
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Table 11: The relative frequencies of detecting granulomas in resection 
and biopsy specimens in each of the 3 diagnostic categories 
  
 
Diagnosis 
 
Granuloma  
Specimen  
Total  Biopsy Resection 
UC Yes 1 0 1 
No 41 0 41 
Total  42 0 42 
CD Yes 4 5 9 
No 6 0 6 
Total  10 5 15 
IC Yes 0 0 0 
No 15 0 15 
Total  15 0 15 
 
P = 0.024 
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Table 12: The frequency of lymphoid aggregates (LA) in relation to 
diagnosis  
 
Diagnosis 
 
LA 
Total 
 
Yes No  
UC 5 37 42 
CD 10 5 15 
IC 3 12 15 
Total 18 54 72 
 
P = 0.00 
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Table 13: The relationship between disease activity and diagnosis 
 
Diagnosis 
 
Activity 
Total 
 
Yes  No  
UC 31 11 42 
CD 11 4 15 
IC 8 7 15 
Total 50 22 72 
 
P = 0.18 
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Table 14: The relationship between disease activity, diagnosis (Dx) and 
medical treatment (Rx) 
 
 
 
Rx 
 
Dx 
Activity  
Total Yes No 
Yes UC 2 6 8 
CD 3 0 3 
IC 1 0 1 
Total  6 6 12 
No UC 29 5 34 
CD 8 4 12 
IC 7 7 14 
Total 44 16 60 
  
P = 0.01 
 
 
 
  
54 
 
Table 15: Frequency and grades of dysplasia in the total IBD population 
(n=72) 
 
Dysplasia Frequency Percent 
No 61 84.7 
Indefinite 2 2.8 
Low grade 6 8.3 
High grade 3 4.2 
Total 72 100.0 
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Table 16: The frequency of dysplasia in each of the 3 categories 
 
Diagnosis 
 
Dysplasia  
Total 
 
No Indefinite Low grade High grade 
UC 33 1 6 2 42 
CD 13 1 0 1 15 
IC 15 0 0 0 15 
Total 61 2 6 3 72 
 
P = 0.056 
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Table 17a: The relative frequency of dysplasia in initial and follow-up 
biopsies in the IBD population 
 
 
Previous Biopsy 
 
Dysplasia 
Total 
 
No  Indefinite Low grade High grade  
Yes 11 0 1 0 12 
No 50 2 5 3 60 
Total 61 2 6 3 72 
 
P = 0.4 
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Table 17b: The relative frequency of dysplasia in initial and follow-up 
biopsies in each diagnostic category   
 
 
 
Diagnosis 
 
Follow up 
biopsy 
Dysplasia  
Total No Indefinite Low grade High 
grade  
UC Yes 7 0 1 0 8 
No 26 1 5 2 34 
Total  33 1 6 2 42 
CD Yes 3 0 0 0 3 
No 10 1 0 1 12 
Total  13 1 0 1 15 
IC Yes 1 0 0 0 1 
No 14 0 0 0 14 
Total  15 0 0 0 15 
 
P = 0.48 
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4.1 Discussion 
 
This is a descriptive retrospective study on inflammatory bowel disease in 
Sudanese patients. Included in the study are all of the patients diagnosed 
as IBD at Soba University Hospital during the period 2006-2010. After 
excluding those with inadequate information, missing slides and tissue 
blocks, or those with disagreement between us and the diagnosing 
pathologist, 72 patients with a diagnosis of IBD are enrolled into the 
study. Clinical and pathological data were collected from the patients’ 
notes and after reviewing all the slides obtained. Some clinical data were 
missing so the analysis was not perfect, however all the pathological data 
were collected after reviewing all the slides and with the aid of our check 
list. 
In this study 72 patients were diagnosed as IBD in the period 2006-2010 
of whom 42 with UC (58.3%), 15 with CD (20.8%) and 15 diagnosed as 
IC (20.8%) (Table1).  Khalifa et al conducted a study at the National 
Centre for Gastrointestinal and Liver diseases in Khartoum, Sudan on 
patients diagnosed with inflammatory bowel disease (IBD) during the 
period between January 1990 and May 2001. Their cohort included 73 
patients with UC (85%) and 12 with CD (15%). Patients labelled as IC 
were not included in that study (7). Although UC is still taking the lead in 
our cohort, we are having relatively more cases of CD. Most studies show 
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a higher prevalence of UC than CD disease in different parts of the 
world(21, 22). Some investigators demonstrated a rise in the incidence of 
Crohn’s disease worldwide(4). Some demonstrated that they are no 
different(23). 
A large percentage of our study population were assigned a label of 
indeterminate colitis which is not a specific diagnosis but a failure to 
classify a case with features of IBD as either UC or CD. Many 
population-based studies and hospital-based surveys have consistently 
found that, in adults, IC accounts for 3%–6% of all initial IBD diagnoses 
in Europe, as well as in Australia, Japan, Lebanon, Saudi Arabia, and 
South Africa(24, 25, 26). Compared to these studies, we are having a large 
number of IC cases. This could be due to the lack of effective 
communication between clinicians and pathologists and the attempts of 
pathologists to diagnose with the minimal data available in the request 
form. We also think that the misconception among pathologists that IC is 
a specific diagnostic category is also contributory. We are planning to 
review all the cases diagnosed as IC after gathering all the clinical and 
radiologic data in an attempt to know the actual prevalence of this 
enigmatic entity.  
During the study period, more cases were diagnosed in the last three 
years than in 2006 and 2007 (Figure1). When reviewing the statistics of 
the endoscopy unit during this 5 year period, it was found that more 
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endoscopies were performed but not to the extent that could explain the 
rise in the number of diagnosed cases. So this rising number of cases 
could be explainable by increased activity of the gastroenterology unit, 
improved diagnostic skills among pathologists and gastroenterologists 
and possibly a genuine increase in incidence. In 2006 there were only two 
resident histopathologists at SUH. By 2008 the number rose to 4 which 
could again explain the better case finding.  
The patients in this study ranged in age from 14 to 87 with a mean age of 
46years (Figure2a). Two peaks were identified; one between 31-40 years 
and another between 51-60 years (Figure2b). Available data from the 
reviewed literature indicate that both UC and CD peak at 15-30 years(27). 
In this study UC peaked between 51-60 years while the peak for CD was 
between 31-40 years (Figure3). This is in agreement with some 
observations from different locales(28, 29).  
Of the 72 patients with IBD, 52 were males (72%) and 20 were females 
(28%) (Figure4a). Both UC and CD were commoner in males than in 
females (Figure4b). Concerning the age and gender specific prevalence, 
UC was most prevalent among men between 51 and 60 years while CD 
was more in men between 31-40 years (Figure5a and 5b). Ekbom et al 
found a higher incidence of UC in older men and a higher incidence of 
CD in young females(22). Different studies from the US also showed the 
same(29). The lower prevalence of both CD and UC in Sudanese females 
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could be attributable in part to the lower number of females attending 
medical clinics. 
There was difficulty collecting data regarding the localities of our 
patients. From what we could gather, we found a higher prevalence of 
IBD (70%, n=33) particularly UC (14 out of 19) among people from 
Central Sudan compared to other regions (Figure 6). The area of Central 
Sudan includes Khartoum and Gezira which are considered urbanized 
relative to other parts of the country. Oliva et al and many others stated 
that the incidence rates for both diseases are higher in urban than in rural 
areas(16, 30). Loftus et al and Lakatos et al demonstrated a rising incidence 
of IBD particularly UC in regions previously thought not to have 
IBD(31,32). Farokhyar et al debated statements of previous epidemiologic 
studies regarding the higher prevalence in industrialized and urban 
communities compared to nonindustrialized and rural ones(33). They 
attributed the differences to the lower number of epidemiologic studies 
and the lack of accessible heath care facilities in rural areas. We so think 
that IBD is no longer a rare entity in Sudan and should no longer stay at 
the bottom of the list of differential diagnoses in gastroenterology 
practice. Improving the medical and diagnostic services in the different 
regions of the country including the centre, together with robust 
epidemiologic studies may blur any differences stated or observed. More 
studies need to be properly conducted to solve this issue. 
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Of the 72 specimens studied, only 5 (7%) were resection specimens. All 
the rest were endoscopic biopsies (93%) (Table2). All the 5 resections 
yielded a diagnosis of CD (Table3). Stated differently, 5 of the 15 cases 
of CD were diagnosed from resection specimens. All UC cases and cases 
designated IC were diagnosed from biopsy specimens. It is implied that 
diagnosing CD from small biopsies is difficult and this might have 
accounted for the large percent of cases labelled as IC from biopsy 
specimen. Also relevant is the high frequency of diagnostic granulomas 
in resections rather than in biopsies. One might also conclude that the rate 
of surgical resection is high for CD compared to UC. Ida Vind et al found 
the rate of surgical intervention in CD to be double that of UC(34). Song 
XM et al did a study on 205 patients with CD from South China; they 
concluded that the rate of surgery for CD was 17.6% at 1 year after onset 
of symptoms, 20.3% at 2 years, 35.2% at 5 years, and 58.3% at 10 
years(35).  
When reviewing the of sites of specimens obtained, which were involved 
by disease, and comparing them to the final diagnosis (tables4-9), it was 
found that CD involved the ileum in 10 (67%) out of the 15 cases 
diagnosed while there was no ileal involvement in UC patients. 
Comparable results were found for the Right colon (40% of CD and only 
7% of UC cases). Moving distally along the colon, UC replaced CD in 
predominance and the rectum was involved in 55% of the cases of UC 
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compared to only 20% of CD cases. Crohn BB in 1932 named the disease 
regional ileitis describing a series of patients with inflammation of the 
ileum, which is the commonest site of involvement by CD(12). Many other 
different studies from different parts of the world confirmed a 
predominant involvement of the terminal ileum and right colon by CD 
with relative rectal sparing. On the other hand UC predominantly affected 
the rectum with declining prevalence as we move proximally(36, 37). It 
seems that IBD in Sudanese patients is following the international 
patterns with regard to sites of intestinal involvement. 
In this study we tried to estimate the frequencies of granulomas and 
lymphoid aggregates in both UC and CD. Of the 15 patients with CD, 
granulomas were detected in 9 (60%) while only one of the 42 patients 
with UC had a granuloma related to crypt rupture (Table10). Granulomas 
were present in all of the 5 resection specimens with CD (100%). On the 
contrary, only 4 out of 10 (40%) CD patients diagnosed from biopsy 
specimens had detectable granulomas (Table11). This indicates the ease 
of detecting granulomas and so of diagnosing CD from resection 
specimens rather than from small biopsies. It is also suggested that 
granulomas are present in CD more than is reported from small biopsy 
specimens. Most studies indicate that granulomas are present in 40-60% 
of CD patients. However the frequencies with which granulomas were 
present differed with the size and number of biopsies taken as well as 
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whether resection or endoscopic biopsy specimens were examined. 
Wolfsm et al reported granulomas to be present in 40-60% of resection 
specimens from patients with CD(38). A similar figure was reported by 
Heimann et al (39). Granuloma was found in 44.6% of 56 patients newly 
diagnosed as CD in a study done by Tamas Molnar et al(40). By contrast 
only 24% of 41 patients with CD had granulomas on endoscopic biopsies 
in a study done by Kumarasinghe et al(41). Although originally thought to 
be diagnostic of CD in the context of IBD, later the occurrence of crypt 
associated mucin granulomas in UC was addressed(42, 43). 
Lymphoid aggregates were significantly more prevalent in CD (10 out of 
15, 67%) than in UC (5 out of 42, 12%) (Table12). This is in keeping 
with most available literature indicating lymphoid aggregates, particularly 
transmural and away from areas of ulceration as a feature of CD rather 
than UC(44, 45). Ricardo et al found that lymphoid aggregates were not 
only more prevalent in CD, but also of a large mean diameter and a more 
basal or transmural location(46).  
Of the 42 patients with UC, 31 (74%) had active disease. In CD, 11(73%) 
out of 15 had active disease (Table13). Of the 31 active UC cases, 2 were 
on medical treatment, indicating failure of response, while the rest were 
newly diagnosed cases. Of the 11 patients with inactive chronic UC, only 
six were on treatment indicating spontaneous remission in the other 5 
patients (Table14). These 5 spontaneous remissions comprised 12% of 
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the total UC population. Comparable statistics was noted for CD patients 
with 4 (27%) out of 15 having inactive disease without treatment. 
However, inactivity in CD does not indicate absence of symptoms. 
Chronic CD lesions may be associated with fibrosis, strictures and 
fistulas which have their own clinical expression in the absence of 
histologic activity. Many different studies confirmed the fluctuating 
nature of activity and remissions in inflammatory bowel disease with 
implications on clinical presentation, diagnosis and management(47, 48).  
In our search for and grading of dysplasia we followed the 4-tiered 
system proposed by Riddell et al in 1983(49). Dysplasia was detected in 
both initial and follow up biopsies in previously diagnosed patients. It 
was hard to determine the duration of the disease in this latter category of 
patients so analysis was not to our ambitions. Taking initial and follow up 
biopsies together, dysplasia was detected in 9 patients (12.5%) of the 72 
IBD patients (Table15). In UC, six had low grade dysplasia, two had high 
grade dysplasia, one was indefinite for dysplasia while 33 had no 
dysplasia. In CD, 13 had no dysplasia, 1 was indefinite for dysplasia and 
1 had high grade dysplasia. None of the 15 patients labelled IC had 
dysplasia (Table16). That is to say, dysplasia is found in 19% of UC 
patients and 7% of CD patients. Of the total 9 patients with dysplasia, 
only one was from follow up biopsies with the remainder detected in 
newly diagnosed patients (Tables17a and 17b). Duration of disease was 
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thus hard to relate to the prevalence and grade of dysplasia. Patients with 
inflammatory bowel disease are well known to have an increased risk for 
the development of dysplasia and adenocarcinoma(50,51,52,53,54,55). Although 
this risk is well established in patients with UC, there is less data 
available in CD. Several studies suggest that given a similar duration and 
extent of disease, the risk of colon cancer is similar in CD and UC(19,56). 
In one study by Bernstein et al, they estimated an increased CRC 
incidence rate for CD and UC of 2.64 and 2.75, respectively(57). In a study 
by Freidman et al, a screening and surveillance program detected 
dysplasia, or cancer, in 16% of 259 CD patients who had follow-up for a 
median of 24 months (51). The incidence of dysplasia in UC worldwide is 
difficult to estimate; studies suggest a 5% incidence of dysplasia after ten 
years and a 25% incidence after 20 years(58,59,60). In our study we had 
dysplasia detected in CD patients but less than that seen with UC. It needs 
a well designed prospective study with determination of disease duration, 
extent, and appearance of dysplasia and carcinoma to be certain about the 
true incidence of dysplasia in IBD in Sudanese patients and whether it is 
truly more prevalent in UC patients.   
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4.2 Conclusion and Recommendations 
 
From the preceding discussion it can be concluded that IBD is no longer 
considered a rare disease entity in Sudan. This is a study from one 
gastrointestinal centre in Sudan and for data collected for only five years. 
Taking into account the other centres, the cumulative annual gathering of 
cases, the annual increment and cases escaping diagnosis, which we think 
are far more numerous than detected ones, one could draw a mental 
picture of the magnitude and resultant burden of IBD in Sudan. 
Ulcerative colitis is more common than CD; however CD is on the rise. 
The high frequency with which IC is diagnosed needs to be investigated 
and corrective action taken. Auditing, clinicopathological correlations 
and integration of all available data or asking for additional data when 
possible seem to be hopefully remedial.  
The lower frequency observed in females for both UC and CD in addition 
to being attributable to genuine epidemiologic differences, might as well 
indicate some gender discrimination in gaining access to medical 
facilities and care. 
What are needed now are robust well designed nationwide epidemiologic 
studies to verify the issues of IBD and the age, gender and locality 
distribution. Also of utmost importance and priority is the enrolment of 
all newly diagnosed patients into a follow up and research programme to 
68 
verify the associations between subtype, disease duration and frequency 
of dysplasia and carcinoma. Also important is the definition and 
monitoring of reproducible criteria for diagnosing and grading dysplasia 
and discriminating it from degenerative and regenerative changes that 
accompany or follow inflammation. Failure to recognize the latter could 
result in a high false positive rate of dysplasia with serious consequences 
to patient management. 
Finally, awareness of the entity and spreading the knowledge are the 
initial prompts for further work and research that would ultimately benefit 
our patients and improves the way they are managed.  
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University of Khartoum 
The Graduate College 
Medical and Health Studies Board 
Questionnaire on 
Inflammatory Bowel Disease in Sudanese Patients:  
A Pathological Study 
 
Personal data 
Name: .............................................. Number: ............................................. 
Medical Record Number: .........................Lab. No.: ......................................... 
Age.......................................................Gender.................................................... 
Occupation........................................... 
Residence.............................................Origin......................................................... 
Year of initial diagnosis.......................................................................................... 
Clinical data 
Adequate data on request form:  YES..................................NO............................ 
Presenting complaints 
..........................................................................................................................................
...................................................................................................................... 
Serology and any ancillary studies 
..........................................................................................................................................
...................................................................................................................... 
Endoscopic appearance 
..........................................................................................................................................
...................................................................................................................... 
Extent         
................................................................................................................................ 
Rectum: Involved...................Spared.....................Relatively spared..................... 
Ileum:   Uninvolved........................................................ 
              Involved:   Mildly ............................Extensively..................................... 
Pattern: Continuous..............................    Patchy.................................................. 
Pathologic specimen: 
Resection  ..............................................................................................................                                        
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Gross description  
..........................................................................................................................................
..........................................................................................................................................
............................................................................................................ 
Biopsy .................................................................................................................... 
Superficial mucosa ........................Mucosa and Submucosa ................................. 
No. of initial biopsies.............................................................................................. 
Site of biopsy (ies) 
Indicated........................................from where?..................................................... 
Not indicated..................................................................... 
Follow up biopsies 
Yes ............................................Number ............................................................... 
NO .......................................................................................................................... 
Histologic Features in initial biopsy 
..........................................................................................................................................
..........................................................................................................................................
..........................................................................................................................................
..........................................................................................................................................
........................................................................................ 
Architecture ........................................................................................................... 
Metaplasia............................................................................................................... 
Mucin depletion...................................................................................................... 
Ulcers...................................................................................................................... 
Inflammation....................................................................................................................
....................................................................................................................... 
Distribution of changes........................................................................................... 
Activity................................................................................................................... 
Lymphoid aggregates.............................................................................................. 
Granulomas............................................................................................................. 
Crypt abscesses....................................................................................................... 
Cryptitis.................................................................................................................. 
Submucosa.............................................................................................................. 
Diagnosis: 
In the original report............................................................................................... 
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After review............................................................................................................ 
Are they consistent: Yes................................... No................................................ 
Histologic features in follow up biopsy (ies), if present 
..........................................................................................................................................
..........................................................................................................................................
............................................................................................................ 
Diagnosis: 
Original .................................................................................................................. 
After review............................................................................................................ 
Dysplasia  
Negative..............Indefinite .................Low grade.................High grade.............. 
If present, time to develop from initial diagnosis................................................... 
 
 
 
 
 
 
 
